This is a StreetInsider.com Premium Only Page

(XERS) – Business Wire

Apr 3, 2024 04:05 PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 2, 2024 07:00 AM Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024 07:02 AM Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Mar 6, 2024 07:00 AM Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Feb 28, 2024 07:00 AM Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Feb 5, 2024 07:00 AM Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Jan 10, 2024 08:00 AM Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Jan 5, 2024 04:05 PM Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024 07:00 AM Xeris Biopharma Updates Its Outlook for 2023

Dec 27, 2023 07:00 AM Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023 07:00 AM Xeris Biopharma Reports Third Quarter 2023 Financial Results

Oct 16, 2023 07:00 AM Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Sep 27, 2023 08:00 AM Xeris Biopharma Announces Private Convertible Note Exchange Transactions

Sep 14, 2023 04:05 PM Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Aug 28, 2023 07:00 AM Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 8, 2023 07:00 AM Xeris Biopharma Reports Second Quarter 2023 Financial Results

Aug 1, 2023 07:00 AM Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

Jul 31, 2023 07:00 AM Xeris Ships One Millionth Gvoke® Unit

Jun 21, 2023 07:00 AM Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Jun 1, 2023 07:00 AM Xeris Biopharma to Participate at the Jefferies Healthcare Conference

May 9, 2023 07:00 AM Xeris Biopharma Reports First Quarter 2023 Financial Results

May 2, 2023 07:00 AM Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Apr 18, 2023 07:00 AM Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

Mar 30, 2023 07:00 AM Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

Mar 29, 2023 04:05 PM Xeris Biopharma Appoints Ricki Fairley to Board of Directors

Mar 8, 2023 06:00 AM Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance

Feb 23, 2023 07:00 AM Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023

Feb 2, 2023 07:00 AM Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023

Jan 30, 2023 07:00 AM Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®

Jan 5, 2023 04:03 PM Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference

Jan 5, 2023 07:00 AM Xeris Biopharma Updates Its Outlook For 2022

Dec 15, 2022 07:00 AM Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

Nov 23, 2022 06:00 AM Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab

Nov 9, 2022 07:00 AM Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

Nov 2, 2022 07:00 AM Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022

Nov 1, 2022 07:00 AM Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology

Oct 20, 2022 06:00 AM Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast

Aug 10, 2022 07:00 AM Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events

Aug 3, 2022 07:30 AM Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

Aug 1, 2022 07:30 AM Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

May 12, 2022 04:02 PM Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

May 11, 2022 07:00 AM Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

May 4, 2022 08:00 AM Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

Mar 16, 2022 07:00 AM Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

Mar 10, 2022 07:00 AM Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

Mar 10, 2022 06:55 AM Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

Mar 4, 2022 07:00 AM Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Feb 9, 2022 07:00 AM Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Jan 31, 2022 07:00 AM Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

Jan 18, 2022 07:00 AM  Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update